Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Cabozantinib in MET-deregulated NSCLC
2024-518386-95-02Phase 2Authorised
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Response Rate. Planned start Feb 2025; status: authorised.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518386-95-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518386-95-02.